Clinical value of miRNA-122 in the diagnosis and prognosis of various types of cancer

MEIYU DAI, LIMIN LI and XUE QIN

Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China

Received January 12, 2018; Accepted February 6, 2019

DOI: 10.3892/ol.2019.10024

Abstract. The present study aimed to systematically analyze the value of microRNA-122 (miRNA-122) in the diagnosis and prognosis of hepatocellular carcinoma (HCC) and other types of cancer. First, the reverse transcription-quantitative polymerase chain reaction method was used to detect the expression levels of miRNA-122 in the serum samples of patients with HCC, benign lesions and healthy volunteers. Next, miRNA-seq data of miRNA-122 from The Cancer Genome Atlas database were used to analyze the differential expression and overall survival rate associated with a variety of types of cancer. Meanwhile, the target gene prediction of miRNA-122 was performed using four different software programs. Finally, 353 significant target genes were identified for Gene Ontology and Kyoto Encyclopedia of Genes and Genomes functional enrichment analysis. Finally, it was demonstrated that the expression levels of miRNA-122 in the HCC group were increased compared with the healthy group (P<0.001), but decreased with respect to the benign group (P<0.001). In addition, the target gene prediction of miRNA-122 and a fetoprotein may further improve the diagnostic accuracy between the HCC and healthy groups (area under the curve, 0.980; 95% confidence interval, 0.958-1.000). It was also demonstrated that miRNA-122 exhibited significantly differential expression and the overall survival rate was predicted for various other types of cancer, including colorectal cancer, renal carcinoma, cholangiocarcinoma, prostate cancer and thyroid carcinoma. Functional enrichment analysis demonstrated that the target genes of miRNA-122 may contribute to the composition of the nucleus and cytoplasm, and regulate a variety of biological processes, including cardiac muscle cell differentiation and glucose metabolic processes via protein biosynthesis, estrogen and glucagon associated signaling pathways. These results revealed that miRNA-122 may be an indispensable biomarker for the diagnosis, prognostic evaluation and targeted therapy in pan-cancer.

Introduction

Hepatocellular carcinoma (HCC) is the sixth most common form of cancer (1) and is the third most common cause of cancer-associated mortality worldwide (2). Hepatitis B virus (HBV) infection is one of the important etiological factors that can lead to liver damage. It was estimated that ~5% of the world population are infected with HBV, especially in China (3). A large proportion of patients with chronic HBV infection may develop necroinflammatory liver disease in the order of increasing severity from sustained liver injury to cirrhosis, hepatic failure and HCC (4). Early diagnosis and treatment are vital for improving the overall survival rate of patients with HCC. The detection of serum a fetoprotein (AFP) may aid the diagnosis of HCC, but its sensitivity is low, especially at the early stage of HCC. Therefore, it is critical to find novel non-invasive serum biomarkers for the independent or combined diagnosis of HCC.

MicroRNA (miRNA), a type of small non-coding single stranded RNA of 18-25 nucleotides in length, can interact with the target genes to suppress their expression by promoting the degradation of target genes or inhibiting translation (5,6). miRNAs have a wide range of functions and are involved in a variety of biological processes, including cell proliferation, growth, differentiation, apoptosis, metabolism and signaling pathway transduction (7,8). They may also serve as important clinical biomarkers for the diagnosis and prognosis of multiple types of cancer (9-11). miRNA-122 is one of the key biomarkers of the miRNAs and constitutes ~52% of the total hepatic miRNome (12). It is the most abundant liver-specific miRNA, which has notable anti-inflammatory effects and is involved in a variety of liver functions (13,14). It has been reported that miRNA-122 exhibited dysregulated expression in HCC tissues, serum and cell lines (15,16); however, contradictory conclusions regarding the differential expression and prognosis of miRNA-122 have been reported (17). In addition, the numerous functions of miRNA-122 in HCC and other types of cancer remain to be further investigated.

In the present study, the clinical value and associated function of miRNA-122 in various types of cancer, particularly...
in HCC were systematically analyzed. Firstly, the expression levels of miRNA-122 in patients with HCC, benign and healthy groups were analyzed and the significance of miRNA-122 and AFP in the differential diagnosis of HCC was evaluated. Secondly, the analysis on the differential expression and survival rate of miRNA-122 in a variety of common cancer types using miRNA-seq data from The Cancer Genome Atlas (TCGA; https://cancergenome.nih.gov/) was performed. Thirdly, the target genes of miRNA-122 were comprehensively predicted for further functional enrichment analysis. Finally, the associated research progress of miRNA-122 was systematically summarized. The content of the present study was progressive and may improve current understanding of miRNA-122 from a macroscopic and comprehensive perspective.

Materials and methods

Serum sample collection. The present study was approved by the Institutional Review Board of the First Affiliated Hospital of Guangxi Medical University (Guangxi, China) and written informed consent was obtained from all individuals in this research project. A total of 150 individuals were enrolled from September 2016 to September 2017, including patients with HCC (50 cases), patients with benign lesions (50 cases) and healthy controls (50 cases). Patent characteristics are presented in Table I. HCC patients were diagnosed by serum AFP concentration analysis and abdominal ultrasonography; diagnoses were confirmed by histopathological examination. In addition, all the serum samples of HCC patients were collected prior to surgical resection. All the serum samples were collected, centrifuged at 2,000 x g for 5 min at room temperature and stored as 500-μl aliquots at -80°C prior to experimental use.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) experiment. Total RNA of serum samples was extracted using the Serum/Plasma miRNA Extraction and Isolation kit DP503. This kit is a newly-developed products specifically for serum and plasma miRNA extraction. Total RNA was reverse transcribed using the miRcute Enhanced miRNA cDNA First Strand Synthesis kit (KR211). All the reagents were obtained from Tiangen Biotech Co., Ltd. (Beijing, China) and all operations were conducted in strict accordance with the manufacturer's protocol. The temperature protocol was as follows: 60 min for miRNA plus A tail reaction and reverse transcription reaction at 42°C; 3 min for enzyme inactivation reaction at 95°C. The RT-qPCR experiment was performed using the reagent of SYBR-Green FP411. The thermocycling conditions of the RT-qPCR were as follows: 15 min for initial template denaturation at 95°C; following 45 cycles of PCR template denaturation for 20 sec at 94°C; annealing and extension for 34 sec at 60°C. The melting/dissociation curve stage was produced following RT-qPCR. The 7500 Real-Time PCR Instrument from Thermo Fisher Scientific, Inc. (Waltham, MA, USA) was used in the detection. U6 was set as an internal reference. The primer of U6: Forward: 5'-AGC GGG AAA TCG TAA AAT AGG-3'; reverse: 5'-CCTTCTTCCCCTCGCCCTCG-3'. The primer of miRNA-122: Forward: 5'-GCGAAA GCATTGTGCAAGGGA-3'; reverse: 5'-CATCACAGACCT GTATTGCC-3'. Calculation of the relative miRNA expression levels was based on 2^ΔΔCq (18).

Statistical analysis. The values in tables were reported as the mean ± standard deviation or number percentage, unless otherwise stated. The receiver operating characteristic curve, area under curve (AUC), sensitivity, specificity, positive predictive value and negative predictive value (NPV) were used to analyze diagnostic accuracy. Youden index=sensitivity-(1-specificity). When the Youden index is at its maximum, the corresponding detection value can be used as the cutoff (19). Student's t-test or one-way analysis of variance (ANOVA) was used to analyze continuous variables where appropriate in this study. Student's t-test was used for the analysis of differential expression between two groups and the one-way ANOVA was used for the analysis of differential expression among more than two groups. Bonferroni's post hoc test was used following the ANOVA. The χ² test or Fisher's exact test was used for the comparisons of differences in the categorical data between groups. A two-tailed P≤0.05 was considered to indicate a statistically significant difference. The aforementioned analyses were performed using IBM SPSS 20.0 (IBM, Corps., Armonk, NY, USA). The scatter plot was produced using GraphPad Prism 5 software (Graphpad Software, Inc., La Jolla, CA, USA).

Differential expression and survival analysis of miRNA-122 in TCGA and literature summary in PubMed. At present, a number of studies have demonstrated that miRNAs or other genes frequently exhibit diversity as clinical markers of cancer. The diagnosis and prognosis of a certain biomarker in clinical pan-cancer is also a popular research model (20,21). Therefore, data of TCGA was thoroughly used to analyze the expression levels of miRNA-122 in a variety of common tumors in this study. Data mining is one of the hot topics in bioinformatics research. The statistical results are more scientific and accurate than simple difference analysis. TCGA is currently a popular database for cancer research. It is a project initiated by the National Cancer Institute and the National Human Genome Research Institute in 2005. It has provided a large amount of genomic data and associated clinical data for researchers in basic and translational medicine for cancer. In this study, analysis of differential expression was performed on the basis that cancer tissues and para-cancerous tissues must be present simultaneously. In TCGA database, the number of tumor tissues are greater than the normal tissues. Certain types of tumor do not contain normal tissue samples. Therefore, the criteria that adjacent normal tissue samples ≥3 was set. The ‘edgeR’ package of R (version 3.3.3; https://www.r-project.org) was used for differential expression analysis based on a False Discovery Rate <0.05 and the absolute value of log2 (fold change) ≥1. In addition, the overall survival analysis of cancers with differentially expressed miRNA-122 was performed using the ‘survival’ package of R (http://bioconductor.org/packages/3.6/bioc/). The present study also searched for relevant references by searching the keyword ‘miRNA-122’ or ‘miRNA-122’ or ‘miR-122’ in PubMed (https://www.ncbi.nlm.nih.gov/pubmed), and summarized the expression and prognosis of miRNA-122 in various types of cancer.

Target gene prediction and functional enrichment analysis. The target gene prediction software available for miRNA is...
In the present study, four classical and common sets of software were selected to predict the target gene of miRNA-122, including miRanda (http://www.microrna.org/) (22), Pic Tar (http://pictar.mdc-berlin.de/) (23), miRDB (http://www.mirdb.org/) (24) and TargetScanHuman (http://www.targetscan.org/vert_71/) (25), respectively. Comparing the target genes of the four types of software, the intersection of any two predictor softwares were selected as candidate target genes for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway functional enrichment analyses. The Venn diagram demonstrating intersections were constructed using the ‘VennDiagram’ package of R. Furthermore, the GO and KEGG pathway analyses are the most common functional enrichment analyses and were performed using the online software, Database for Annotation, Visualization and Integrated Discovery (DAVID), version 6.8 (https://david.ncifcrf.gov/) (26). The selection criteria for functional items were in accordance with P≤0.05 and count number ≥2.

Results

Clinical characteristics. The clinical information and laboratory biomarker analysis of the different groups are presented in Table I. For statistical analysis, all the participants were divided into three groups: Including HCC (50 cases), benign (HBV and cirrhosis, 50 cases) and healthy (50 cases). There was no statistically significant difference between the age and gender of the studied groups as they were matched with each other. However, there was a significant difference between the different groups regarding the clinical biomarker AFP (P<0.001 for all comparisons).

Different expression of miRNA-122 among three groups. The expression levels of miRNA-122 were detected among the HCC, benign and healthy groups. The results indicated that there was a significant difference in the expression levels of miRNA-122 among the three groups (Fig. 1). Compared with the healthy group, the HCC and benign groups exhibited significantly increased expression levels of miRNA-122 (P<0.001). In addition, the expression levels of miRNA-122 between the HCC and benign groups were compared, and it was demonstrated that the benign group exhibited significantly higher expression levels of miRNA-122 compared with the HCC group (P=0.007). Overall, the expression levels of miRNA-122 in the healthy, HCC and benign groups demonstrated a step-wise increase (healthy group < HCC group < benign group); there was a statistically significant difference between the different groups regarding the clinical biomarker AFP (P<0.001 for all comparisons).
groups (P<0.001; Fig. 1C). Therefore, miRNA-122 can be used not only for the identification of HCC and normal controls, but also for the identification of HCC and benign lesions. There is also a study demonstrating that the serum level of miRNA-122 in patients with hepatitis is increased compared with in HCC patients (27). The experiments of the present study confirmed this.

**Subgroup analysis of miRNA-122 in individuals with HBV.** In the study of the clinical markers of HCC, it is particularly important to analyze individuals with hepatitis B. Therefore, subgroup analysis (HBV-positive and -negative groups) of the expression levels in individuals with hepatitis B was performed in the present study. The results are presented in Table II. There was no statistically significant difference in the expression levels of miRNA-122 between the positive and negative HBV groups. However, the concentration of AFP was significantly associated with HBV infection in the HCC (P=0.03) and HCC + Benign group (P=0.003). In HBV-infected individuals, AFP concentrations were increased compared with HBV negative patients.

**Diagnostic accuracy of miRNA-122, AFP and miRNA-122 + AFP.** In the previous differential expression analysis, it was demonstrated that the miRNA-122 expression levels were significantly different between the HCC vs. healthy groups and the HCC vs. benign groups (Fig. 1). Additionally, AFP has also been recognized as a serological biomarker for the diagnosis of HCC. Therefore, the diagnostic value of assessing miRNA-122, AFP and miRNA-122 + AFP in HCC was investigated in the present study (Table III). The diagnostic sensitivity of miRNA-122 (sensitivity, 90%) was increased compared with AFP (sensitivity, 86%) and the combination of the two biomarkers could further improve the diagnostic accuracy between the HCC and healthy groups (AUC, 0.980; 95% CI, 0.958-1.000). However, the diagnostic sensitivity and specificity of miRNA-122 were poor between HCC and benign groups (sensitivity, 64%; specificity, 62%).

**Differential expression and survival analysis of miRNA-122 by pan-cancer analysis of TCGA database.** It is an indisputable fact that miRNA-122 is highly expressed in HCC. However, the expression of miRNA-122 in other types of tumor requires further investigation. In the present study, the differential expression of miRNA-122 was analyzed in a variety of common tumors using the publicly available data of TCGA database. Following strict screening, 17 types of cancer were selected to analyze the differential expression of miRNA-122 between cancerous and adjacent normal tissues; the results are presented in Table IV. The expression levels of miRNA-122 were significantly upregulated in eight types of cancer, including colorectal carcinoma, breast, kidney and lung cancers, prostate adenocarcinoma, stomach adenocarcinoma, thyroid carcinoma and uterine cancer. In addition, miRNA-122 was reported to be significantly downregulated in cholangiocarcinoma and HCC (Table IV). Simultaneously, survival analysis was performed in the types of cancer with differentially expressed miRNA-122. The results of survival analysis demonstrated that high expression levels of miRNA-122 were associated with poor prognosis in kidney

| Measurement | HCC (n=42) | HBV (n=50) | HBV + Benign (n=26) |
|-------------|------------|------------|---------------------|
| miRNA-122, mean ± SD | 23.5±29.6 | 9.5±8.3 | 64.3±93.7 |
| AFP, ng/ml | 12.588±21.920.6 | 639.1±1,254.2 | 33.0±75.0 |

Sample sizes: HCC, n=50; HBV, n=50; HBV + Benign, n=26; P-value was calculated using Students t test following normalization (log2 conversion). HCC, hepatocellular carcinoma; miRNA, microRNA; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; miRNA, microRNA.
Table III. Diagnostic value of miRNA-122, AFP and miRNA-122 + AFP.

| Parameter          | HCC vs. Healthy | HCC vs. Benign |
|--------------------|-----------------|----------------|
|                    | miR-122 | AFP      | miR-122 + AFP | miR-122 | AFP      | miR-122 + AFP |
| Sensitivity, %     | 90.0    | 86.0     | 90.0         | 64.0    | 86.0     | 86.0         |
| Specificity, %     | 94.0    | 100.0    | 100.0        | 62.0    | 80.0     | 80.0         |
| AUC (95% CI)       | 0.954   | 0.961    | 0.980        | 0.667   | 0.878    | 0.876        |
| (0.907-1.000)      | (0.927-0.996)| (0.958-1.000)| (0.562-0.772)| (0.811-0.944)| (0.808-0.944) |
| PPV, %             | 94.0    | 1.0      | 1.0          | 63.0    | 81.0     | 81.0         |
| NPV, %             | 90.0    | 88.0     | 91.0         | 63.0    | 85.0     | 85.0         |
| Cutoff             | 2.80    | 8.78     |              | 14.29   | 8.59     |              |

HCC, hepatocellular carcinoma; AFP, α-fetoprotein; miR, microRNA; AUC, area under curve; PPV, positive predictive value; NPV, negative predictive value.

Table IV. Differential expression analysis of microRNA-122 in 17 types of cancer from The Cancer Genome Atlas database.

| Cancer type                        | Abbreviation | Cancer/normal, n | False discovery rate | LogFC |
|------------------------------------|--------------|------------------|----------------------|-------|
| Colorectal carcinoma               | CRC          | 619/11           | 4.62x10^-2a          | 8.18  |
| Adrenal gland carcinoma            | AGC          | 264/3            | 1.00                 | 7.02  |
| Cholangiocarcinoma                 | CHOL         | 36/9             | 5.01x10^-8a          | -4.16 |
| Bladder urothelial carcinoma       | BLCA         | 418/19           | 3.59x10^-1           | 2.04  |
| Brain glioma                       | BG           | 530/5            | 1.00                 | 0.45  |
| Breast cancer                      | BC           | 1.103/104        | 1.80x10^-13a         | 7.34  |
| Cervical cancer                    | CC           | 309/3            | 1.00                 | 6.52  |
| Esophageal carcinoma               | ESCA         | 187/13           | 2.53x10^-1           | 3.00  |
| Head and neck squamous cell carcinoma | HNSC   | 525/44           | 7.73x10^-2           | -0.81 |
| Kidney cancer                      | KC           | 1.074/147        | 9.40x10^-36a         | 5.43  |
| Hepatocellular carcinoma           | HCC          | 375/50           | 1.14x10^-3a          | -0.61 |
| Lung cancer                        | LC           | 999/91           | 9.40x10^-11a         | 5.75  |
| Pancreatic adenocarcinoma          | PAAD         | 179/4            | 1.00                 | 0.35  |
| Prostate adenocarcinoma            | PRAD         | 499/52           | 1.19x10^-6a          | 3.84  |
| Stomach adenocarcinoma             | STAD         | 446/45           | 9.86x10^-4a          | 3.44  |
| Thyroid carcinoma                  | THCA         | 514/59           | 7.77x10^-3a          | 1.64  |
| Uterine cancer                     | UC           | 603/33           | 3.28x10^-5a          | 6.90  |

*p<0.05. LogFC, log_2 (fold-change).

cancer, but good in patients with HCC (P=0.012 and P<0.001). However, there was no significant effects on the prognoses of other types of cancer (Fig. 2).

Literature summary of the expression and prognosis of miRNA-122 via pan-cancer analysis. In addition to experimental validation and public database mining, the collective findings of the literature were also valuable. Information from available articles on the PubMed database on differential expression levels and prognostic value of miRNA-122 in a variety of cancer types was summarized. The results are presented in Table V. Literature data of the differential expression and survival analysis of miRNA-122 between HCC and adjacent normal tissues were consistent with the results of TCGA analysis. Additionally, the results in colorectal cancer, renal carcinoma, cholangiocarcinoma, prostate cancer and thyroid carcinoma were the same. However, there were inconsistent conclusions of particular types of cancer, including breast and gastric cancer. The inconsistencies need to be further studied.

Target gene prediction of miRNA-122 and functional enrichment analysis. Due to the limitations of using a single prediction software of miRNA target genes, four commonly used miRNA target gene prediction software were used to simultaneously analyze. The intersection of two or more of the employed software was selected. Finally, 353 miRNA-122 target genes were included for functional enrichment analysis (Fig. 3). MEF2C, MASP1, SLC52A2, NONO, BRPF1, USP53, VPS4A, CCAR1,
HIF0 and KIF5B were the top 10 of the 353 target genes, and the others are not illustrated. In the present study, GO and KEGG pathway analysis were carried on the target genes of miRNA-122. Following the enrichment analysis by DAVID
The present study analyzed the expression levels of miRNA-122 in tissues and serum samples of various types of cancer systematically by RT-qPCR analysis, TCGA and literature. The lower expression levels of miRNA-122 in HCC patients compared with in healthy controls (50,51). The expression levels of miRNA-122 in the serum of HBV-positive patients with HCC were frequently decreased compared with patients with benign liver lesions (27), which was consistent with the results of serological analysis in the present study. Meanwhile, miRNA-122 and AFP analyses were combined for diagnosis in the present study, which may have improved the non-invasive diagnostic accuracy of HCC.

TCGA database is one of the most widely used public data platforms for a variety of types of cancer. Following screening, 17 common cancer types were included in the differential expression analysis of miRNA-122. Finally, it was demonstrated that miRNA-122 was differentially expressed in 10 types of tumor from TCGA. However, by summarizing the reported literature, differential expression of miRNA-122 in a number of types of cancer was also demonstrated. Additionally, there are several consistent types of cancer between the two summary methods, including HCC (52), renal carcinoma (33) and colorectal cancer (53); however, certain results were inconsistent. The number of samples, fixed tumor type in TCGA, the difference in detection methods and platforms, etiology or pathological classification, and clinical features, may lead to inconsistent results. In future studies, an in-depth exploration of inconsistencies can also be conducted. In addition, the prognostic value of miRNA-122 in a variety of cancer was also analyzed and summarized. Through the analysis of TCGA data, it was demonstrated that the expression levels of miRNA-122 could affect the overall survival rate of HCC and renal carcinoma. In addition to the association between miRNA-122 and the prognosis of HCC, it was also demonstrated that the low expression levels of miRNA-122 predicted the poor prognosis of glioma (54), gastric cancer (55) and leukemia (56) by literature retrieval. However, there were disagreements regarding the association between the expression levels of miRNA-122 and the prognosis of HCC in the serum or plasma. Specific studies revealed that high expression of miRNA-122 indicated poor prognosis (57,58), but certain findings suggested that the high expression of miRNA-122 predicted improved prognosis (59,60); however, further investigation is required. Although there are a number of reports on miRNA-122, most of them are limited to a certain cancer, especially liver cancer. In the present study, a more comprehensive pan-cancer analysis of miRNA-122 was performed in combination with the current popular TCGA high-throughput sequencing database and associated literature. The present study is more general, gives a summary and can provide a macro guidance for the diagnosis, prognosis and treatment of multiple cancers in clinical practice.

In this study, the target genes of miRNA-122 were predicted using numerous platforms and the GO and KEGG enrichment analyses were performed on the reported target genes. The results of GO enrichment analysis demonstrated that the target genes of miRNA-122 may contribute to the composition of...
Figure 4. Gene ontology terms enrichment analysis of target genes of miRNA-122 by Database for Annotation, Visualization and Integrated Discovery software. Proportional distribution and EnrichmentScore [-log(P-value)] in (A) ‘biological process’; (B) ‘cellular component’ and (C) ‘molecular function’.
the nucleus and cytoplasm, and regulate cardiac muscle cell differentiation in a variety of biological processes, including cardiac muscle cell differentiation and glucose metabolic processes through protein binding. So far, numerous articles have reported that miRNA-122 was closely associated with heart-related diseases, obesity and diabetes (37,61,62,64). For example, the expression of miR-122 was involved in hypoxia-induced cardiomyocyte injury (37). In experiments with miniature pigs, researchers demonstrated that increases in weight and cholesterol levels could lead to a decline in the expression levels of miRNA-122, which supported the association of miRNA122 in obesity (61). KEGG pathway analysis revealed that the target genes were mainly enriched in protein biosynthesis, estrogen and glucagon associated signaling pathways. Munagala et al (62) reported that miRNA-122 was one of the significantly modulated miRNAs in the process of estrogen-mediated mammary carcinogenesis. miRNA-122 participated in the regulation of insulin resistance, diabetes and metabolic syndrome, which were all likely to be associated with glucagon related signaling pathways (42).

In conclusion, the clinical significance of miRNA-122 was systematically analyzed from multiple perspectives in this study. The diagnostic value of miRNA-122 between the HCC and healthy control via serology was further demonstrated, and the differential diagnostic value in patients with HCC compared with in benign lesions was also analyzed. In addition, it was demonstrated that miRNA-122 exhibited significant differential expression and prognostic ability in various types of cancer via TCGA database and literature review. Finally, a number of important biological functions and regulatory mechanisms have been reported through the enrichment analysis of the miRNA-122 target genes. These analyses demonstrated that miRNA-122 may be an indispensable biomarker for the diagnosis, prognostic evaluation and targeted therapy in a variety of cancer types.

Acknowledgements

The authors would like to thank Mrs Yujie Huang (Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Guangxi, China) for her work in language editing.

Figure 5. Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of miRNA-122 target genes by Database for Annotation, Visualization and Integrated Discovery software.

Funding

No funding was received.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in the TCGA repository (https://cancergenome.nih.gov/).

Authors’ contributions

MD contributed to the writing of the paper and bioinformatics analysis; LL contributed to the sample collection and experiment; XQ contributed to the overall design of this paper.

Ethics approval and consent to participate

The present study was approved by the Institutional Review Board of the First Affiliated Hospital of Guangxi Medical University and written informed consent was obtained from all individuals in this research project.

Patient consent for publication

All the patients have written informed consent for the publication of any associated data or accompanying images.

Competing interests

The authors declare they have no competing interests.

References

1. Forner A, Llovet JM and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
2. Yang X, Xie X, Xiao YF, Xie R, Hu CJ, Tang B, Li BS and Yang SM: The emergence of long non-coding RNAs in the tumorigenesis of hepatocellular carcinoma. Cancer Lett 360: 119-124, 2015.
3. El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 142: 1264-1273 el, 2012.
4. Liu CJ and Kao JH: Global perspective on the natural history of chronic hepatitis B: role of hepatitis B virus genotypes A to J. Semin Liver Dis 33: 97-102, 2013.
5. Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379, 2010.
6. Fukaya T and Tomari Y: MicroRNAs mediate gene silencing via multiple different pathways in drosophila. Molecular cell 48: 2929-2941, 2017.
7. Takasaki S: Roles of microRNAs in cancers and development. Methods Mol Biol 1218: 375-413, 2015.
8. Zhang LF, Jiang S and Liu MF: MicroRNA regulation and analytical methods in cancer cell metabolism. Cell Mol Life Sci 74: 2929-2941, 2017.
9. Castro D, Moreira M, Gouveia AM, Pozza DH and De Mello RA: MicroRNAs in lung cancer. Oncotarget 8: 81679-81685, 2017.
10. Ferracin M, Lupini L, Mangolini A and Negrini M: Circulating non-coding RNA as biomarkers in colorectal cancer. Adv Exp Med Biol 937: 171-181, 2016.
11. Endzelniņš E, Melne V, Kalina Z, Lietuvietis V, Riekstaņa U, Llorente A and Linē A: Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: A systematic review. Mol Cancer 15: 41, 2016.
12. Bandiera S, Pfeffer S, Baumert TF and Zeisel MB: miR-122-a key factor and therapeutic target in liver disease. J Hepatol 62: 448-457, 2015.
13. Wen J and Friedman JR: miR-122 regulates hepatic lipid metabolism and tumor suppression. J Clin Investig 122: 2773-2776, 2012.

No funding was received.
et al: Identification and characterization of inter-
miR-122 promotes metastasis of clear-
cell renal cell carcinoma by downregulating Dicer. Int J Cancer 142: 547-560, 2018.

14. Gao, Y. He Y, Ding J, Wu K, Hu B, Liu Y, Wu Y, Guo B, Shen Y, Landi D, et al: An insertion/deletion polymorphism at miR-122-binding site in the interleukin-1alpha 3' untranslated region: Risk for hepatocellular carcinoma. Carcinogenesis 30: 2064-2069, 2009.

15. Ma J, Li T, Han X and Yuan H: Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma. J Cancer Res Clin Oncol 144: 207-214, 2018.

16. Cavazza A, Viola C, Gao S, Parkinson E, Bosco C, Olivero A, Rosso C, Ciancio A, Pellicano R, Saracco GM, et al: Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFTP and PIVKA-II. Panminerva Med 59: 283-289, 2017.

17. Dimer Y, Xu M, Wang AN, Zhou WF and Huang L: Circulating miRNAs as novel diagnostic biomarkers in hepatocellular carcinoma detection: A meta-analysis based on 24 articles. Oncotarget 8: 66402-66413, 2017.

18. Nadert M, Pazozi A, Arefian E, Hashemi SM, Jamshidi-Adegani F, Ghomalamdar M, Soltani S, Azadmanesh K, Mirab Simcice S, Merat S, et al: Two triacylglycerol pathway genes, CTDNEP1 and LPIN1, are down-regulated by hsa-miR-122-5p in hepatocytes. Arch Iran Med 20: 165-171, 2017.

19. Schisterman EF, Perkins NJ, Liu A and Bondell H: Optimal cut-point and its corresponding Youden Index to discriminate individuals using pooled blood samples. Epidemiology 16: 73-81, 2005.

20. Chen X, Dai M, Zhu H, Li J, Huang Z, Liu X, Huang Y, Chen J and Dai S: Evaluation on the diagnostic and prognostic values of long non-coding RNA BLACAT1 in common types of human cancer. Med Oncol 34: 160, 2017.

21. Goldvasser H, Gutkin A, Beery E, Edel Y, Nordenberg J, Wolah O, Rabizadeh E, Uziel O and Lahav M: Characterisation of blood-derived exosomal hTERT mRNA secretion in cancer patients: A potential pan-cancer marker. J Cancer 117: 385-397, 2016.

22. Betel D, Wilson M, Gabow A, Marks DS and Sander C: The microRNA.org resource: Targets and expression. Nucleic Acids Res 33: 102-105, 2005.

23. Grun D, Mattick JS, Cartwright L and Sander C: The microRNA.org resource: Targets and expression. Nucleic Acids Res 33: 102-105, 2005.

24. Wang T, Li F, Geng W, Ruan Q and Shi W: MicroRNA-122 ameliorates corneal allograft rejection through the downregulation of its target CPEB1. Cell Death Discov 3: 17021, 2017.

25. Selmaj J, Cichalewska M, Namiecinis G, Galazka G, Horzelski W, Selmaj KW and Mycko MP: Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. Ann Neurol 81: 703-717, 2017.

26. Trzybulska D, Bobjer J, Giewercman A and Tsatsanis C: Serum microRNAs in male subfertility -biomarkers and a potential pathogenic link to metabolic syndrome. J Assist Reprod Genet 34: 1277-1282, 2017.

27. Couloaur C, Factor VM, Andersen JB, Durkin ME and Thorgersson SS: Loss of mir-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 28: 3526-3536, 2009.

28. Jin Y, Wang J, Han J, Luo D and Sun Z: MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-catenin signaling pathway. Exp Cell Res 360: 210-217, 2017.

29. Chen X, Dai M, Zhu H, Liu X, Li J, Li X, Liu Y, Chen CH, Wang J, Hu B, Liu Y, Wu Y, Guo B, Chen Y and Liu Y: Elevated plasma miRNA-122, -140-3p, -720, -2861, and -3149 during early period of acute coronary syndrome are derived from peripheral blood mononuclear cells. PLOS One 12: e0184256, 2017.

30. Zhuang Z, Li H, Chen S, Li Y, Cui Z and Ma J: Knockdown of miRNA-122-5p protects H9c2 cardiomyocytes from hypoxia-induced apoptosis and promotes autophagy. Med Sci Monit 23: 4284-4290, 2017.

31. Satriauskiené A, Navickas R, Laučevičius A and Huber HJ: Identifying differential miR and gene consensus patterns in peripheral blood of patients with cardiovascular diseases from literature data. BMC Cardiovasc Disord 17: 173, 2017.

32. Blum A, Yehuda H, Geron N and Meerson A: Elevated levels of miR-122 in serum may contribute to improved endothelial function and lower oncologic risk following bariatric surgery. Isr Med Assoc J 19: 620-624, 2017.

33. Jonsson A, Daniellson KM, Benton MC, Ziegler O, Shah R, Stubbs RS, Das S and Macartney-Coxson D: miRNA signatures of insulin resistance in obesity. Obesity (Silver Spring) 25: 1734-1744, 2017.

34. Zhao H, Shen J, Daniel-McDougall C, Wu X and Chow WH: Plasma MicroRNA signature predicting weight gain among Mexican-American women. Obesity (Silver Spring) 25: 958-964, 2017.

35. Willate P, Skroblin P, Moschen AR, Yin X, Kaudewitz D, Zampetaki A, Barwari T, Whitehead M, Ramirez CM, Goedeke L, et al: Circulating MicroRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes 66: 347-357, 2017.

36. Bijkker K, Florijn BW, Khaireoun M, Dujs JMGJ, Oacak G, de Vries APJ, Schaapherder AF, Mallat MKJ, de Fijter JW, Rabelink TJ, et al: Acute rejection after kidney transplantation associates with circulating MicroRNAs and vascular injury. Transplant Direct 3: e174, 2017.

37. Wang T, Li F, Geng W, Ruan Q and Shi W: MicroRNA-122 ameliorates corneal allograft rejection through the downregulation of its target CPEB1. Cell Death Discov 3: 17021, 2017.

38. Zhao H, Shen J, Daniel-McDougall C, Wu X and Chow WH: Plasma MicroRNA signature predicting weight gain among Mexican-American women. Obesity (Silver Spring) 25: 958-964, 2017.

39. Blum A, Yehuda H, Geron N and Meerson A: Elevated levels of miR-122 in serum may contribute to improved endothelial function and lower oncologic risk following bariatric surgery. Isr Med Assoc J 19: 620-624, 2017.

40. Jonsson A, Daniellson KM, Benton MC, Ziegler O, Shah R, Stubbs RS, Das S and Macartney-Coxson D: miRNA signatures of insulin resistance in obesity. Obesity (Silver Spring) 25: 1734-1744, 2017.

41. Zhao H, Shen J, Daniel-McDougall C, Wu X and Chow WH: Plasma MicroRNA signature predicting weight gain among Mexican-American women. Obesity (Silver Spring) 25: 958-964, 2017.
MiR-122 promotes renal cancer and high expression of miR-122 as a potential diagnostic and prognostic indicator in human glioma. Neurol Sci 38: 1087-1092, 2017.

Netto GJ, Munari E, Marchionni L, Chitre A, Nientiedt M, Deng M, Schmidt D, Perner S, Rahal P, Gonçalves JD, Jasiulionis MG, De Freitas Calmon M and Conceição AL: Downregulation of OCLN and GAS1 in clear cell renal carcinoma and papillary renal cell carcinoma. Hum Pathol 45: 1166-1172, 2017.

Cho HJ, Kim JK, Nam JS, Wang HJ, Lee JH, Kim BW, Kim SS, Noh CK, Shin SJ, Lee KM, et al: High circulating microRNA-122 expression is a poor prognostic marker in patients with hepatitis B virus-related hepatocellular carcinoma who undergo radiofrequency ablation. Clin Biochem 48: 1073-1078, 2015.

Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, Xu N and Xie Y: Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One 9: e109347, 2014.

Xu Y, Bu X, Dai C and Shang C: High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients. Tumour Biol 36: 4773-4776, 2015.

Köhler V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberjag H, Welker MW, Elhedawy M, Zeuzem S, Piiper A and Waidmann O: Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer 49: 3442-3449, 2013.

Cirera S, Birck M, Busk PK and Fredholm M: Expression profiles of miRNA-122 and its target CAT1 in minipigs (Sus scrofa) fed a high-cholesterol diet. Comp Med 60: 136-141, 2010.

Munagala R, Aqil F, Vadhanam MV and Gupta RC: MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention. Canc Lett 339: 175-184, 2013.

Balasubramanian VR, Zander TS, Reddy KV, Dong W, Thakur S, Pan C and Roychowdhury P: A highly sensitive and specific to osteosarcoma by microRNA response elements. Mol Med Rep 11: 739-745, 2015.

Ergün S, Ulaslı M, Içgi YZ, Içgi M, Kırkbeş S, Borazan E, Balık A, Yumrutaş Ö, Camci C, Cakmak EA, et al: The association of the expression of miR-122-5p and its target ADAM10 with human breast cancer. Mol Biol Rep 42: 497-505, 2015.

Han Z, Tao J, Cao Q, Zhou W, Xu Z, Zhao C, Tan R and Gu M: MiR-122 promotes renal cell carcinoma proliferation by targeting Sprouty2. Tumour Biol 39: e101038317691184, 2018.

Wotschalsky Z, Busch J, Jung M, Kempensteffen C, Weikert S, Schaser KD, Melcher I, Klici E, Müller K, Kristiansen G, et al: Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. Clin Chim Acta 416: 5-10, 2013.